Galantamine, an inhibitor of acetylcholinesterase, promotes hippocampal neurogenesis, but the exact mechanism for this is not known. In the present study, we examined the mechanisms underlying the effects of acute galantamine on neurogenesis in the mouse hippocampus. Galantamine (3 mg/kg) increased the number of 5-bromo-2′-deoxyuridine (BrdU)-positive cells in the subgranular zone of the dentate gyrus. This effect was blocked by the muscarinic receptor antagonist scopolamine and the preferential M 1 muscarinic receptor antagonist telenzepine, but not by the nicotinic receptor antagonists mecamylamine and methyllycaconitine. Galantamine did not alter the ratio of neuronal nuclei (NeuN)-or glial fibrillary acidic protein (GFAP)-positive cells to BrdU-labeled cells in the subgranular zone and granule cell layer. Galantamine (1, 3 mg/kg) promoted the survival of 2-wk-old newly divided cells in mice in the granule cell layer of the dentate gyrus, whereas it did not affect the survival of newly divided cells at 1 and 4 wk. Galantamine-induced increases in cell survival were blocked by the α7 nicotinic receptor antagonist methyllycaconitine, but not by scopolamine. Bilateral injection of recombinant IGF2 into the dentate gyrus of the hippocampus mimicked the effects of galantamine. The effects of galantamine were blocked by direct injection of the IGF1 receptor antagonist JB1. These findings suggest that galantamine promotes neurogenesis via activation of the M 1 muscarinic and α7 nicotinic acetylcholine receptors. The present study also suggests that IGF2 is involved in the effects of galantamine on the survival of 2-wk-old immature cells in the granule cell layer.
Introduction
Galantamine, an acetylcholinesterase inhibitor, is used for the treatment of patients with Alzheimer's disease. The drug interacts with the nicotinic receptor at binding sites separate from those for acetylcholine and acts specifically to enhance the activity (sensitize) of nicotinic receptors in the presence of acetylcholine (Maelicke and Albuquerque, 2000; Maelicke et al., 2001; Dajas-Bailador et al., 2003; Samochocki et al., 2003) . These allosteric potentiating effects on the nicotinic receptor appear to play a key role in the clinical effectiveness of galantamine, as the severity of cognitive impairment in Alzheimer's disease correlates with loss of nicotinic receptors (Nordberg et al., 1995; Perry et al., 2000) . In addition to nicotinic receptors, the muscarinic receptor is also involved in the pharmacological effects of galantamine. Wadenberg et al. (2011) reported that muscarinic receptors may be involved in the antipsychotic-like effects of galantamine. We have shown that galantamine improves isolation-rearing-induced deficits of prepulse inhibition through a muscarinic-receptor-mediated mechanism (Ago et al., 2011a, b; Koda et al., 2011; Matsuda, 2013) . However, the receptor pharmacology of the clinical effectiveness of galantamine is not known. Following receptor activation, galantamine increases extracellular dopamine levels in the prefrontal cortex in rats (Schilström et al., 2007) and mice (Yano et al., 2009) . Furthermore, Jin et al. (2006) reported that galantamine promotes neurogenesis in the subgranular zone of the hippocampus and the subventricular zone of the lateral ventricles in mice, when it was administered daily for 14 d. Previous studies have shown that brain-derived neurotrophic factor (Lee et al., 2002; Rossi et al., 2006) , nerve growth factor (Frielingsdorf et al., 2007) , vascular endothelial growth factor (Schänzer et al., 2004) , insulin-like growth factor 1 (IGF1) (Anderson et al., 2002; Llorens-Martín et al., 2009 ) and IGF2 (Agis-Balboa et al., 2011; Bracko et al., 2012) are involved in adult hippocampal neurogenesis. Thus, it is likely that the effects of galantamine on hippocampal neurogenesis are mediated by neurotrophic/ growth factors. In this line, we have recently demonstrated that galantamine increased hippocampal IGF2 expression via activation of the α7 nicotinic receptor in mice (Kita et al., 2013) .
In the subgranular zone of the hippocampal dentate gyrus of adult mammals, neurogenesis is sustained throughout life (Eriksson et al., 1998) . Newborn neurons in the subgranular zone survive, migrate, and differentiate into mature neurons in the granule cell layer, where they are functionally incorporated into the hippocampal circuitry (Aasebø et al., 2011; Ming and Song, 2011) . Previous studies show that cholinergic stimulation promotes the proliferation and survival of neural precursor cells (Berger et al., 1998; Coronas et al., 2000; Ma et al., 2000) and that dysfunction of the cholinergic system impairs neurogenesis Harrist et al., 2004; Mohapel et al., 2005) . However, it is not known whether IGF2 is involved in neurogenesis induced by cholinergic stimulation.
The present study examined the effects of galantamine on adult mouse hippocampal neurogenesis, focusing on proliferation, differentiation, and survival of newly divided cells. We examined the role of IGF2 in galantamine-induced hippocampal neurogenesis, in view of the recent finding that galantamine increases IGF2 levels in the hippocampus (Kita et al., 2013) . We demonstrate that acute treatment with galantamine promotes the proliferation of adult neural progenitor cells via M 1 muscarinic receptor activation and enhances the survival of newly divided cells at 14-16 d old via activation of the α7 nicotinic receptor, and that the latter effects may be mediated by IGF2.
Method

Animals and drugs
The experimental procedures involving the use of animals in this work were conducted according to the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society. Every effort was made to minimize animal suffering and to reduce the number of animals used. Eight-weekold male ddY mice were obtained from Shimizu Laboratory Supplies Co., Ltd (Japan) and housed in cages (24 × 17 × 12 cm) of five to six animals under controlled environmental conditions (22 ± 1°C; 12:12-h light-dark cycle, lights on at 08:00 h, food and water provided ad libitum) for 1 wk before use in the experiments. We used 367 mice in total. The following drugs were used: 5-bromo-2′-deoxyuridine (BrdU), mecamylamine, methyllycaconitine, oxotremorine, physostigmine, scopolamine, and telenzepine (Sigma, USA), and galantamine, donepezil, and PHA-543613 (Tocris Bioscience, UK). These drugs were dissolved in saline (0.9% solution of NaCl). All drugs were administered in a volume of 10 ml/kg intraperitoneally (i.p.) (galantamine, donepezil, BrdU, mecamylamine, methyllycaconitine, oxotremorine, physostigmine) or subcutaneously (s.c.) (PHA-543613, scopolamine, telenzepine). The doses of galantamine and donepezil used here were selected according to previous studies (Csernansky et al., 2005; Schilström et al., 2007; Wang et al., 2007; Koda et al., 2008; Tanaka et al., 2009; Noda et al., 2010) . Physostigmine was used at a dose that elevates acetylcholine levels in the hippocampus (Erb et al., 2001) , and oxotremorine was used at a dose that improves apomorphine-or isolation rearinginduced deficits in prepulse inhibition (Yano et al., 2009; Koda et al., 2011) . Recombinant IGF2 (Sigma, USA), JB1 (Bachem Biosciences, USA), and anti-IGF2 receptor antibodies (R&D Systems, USA) were used.
To evaluate the proliferation and differentiation of newly divided cells, mice received two injections at 12 h intervals of BrdU (50 mg/kg) 24 h after the injection of the test drugs. Over 3 consecutive days, mice received three intraperitoneal injections of BrdU (50 mg/kg) per day, every 4 h, to assess the survival of newly divided cells. Animals were sacrificed either 12 h after the last BrdU injection to evaluate the proliferation of newly divided cells, or 28 d after the last BrdU injection to evaluate the differentiation of newly divided cells, or 42 d after the last BrdU injection to assess the survival of newly divided cells.
Injection of drugs into the dentate gyrus of the hippocampus
Fifteen days after the last injection of BrdU, mice were deeply anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and positioned in a stereotaxic apparatus. Bilateral injections of drugs into the dentate gyrus of the hippocampus were performed according to the method of Agis-Balboa et al. (2011) . A burr hole was made using the following coordinates (anteroposterior −1.7 mm; lateral ±1 mm; ventral 2 mm, relative to bregma and skull) and stock solutions of IGF2 (1 μg/μl in 0.1% BSA (bovine serum albumin) in sterile phosphatebuffered saline (PBS; pH 7.4)), the IGF1 receptor antagonist JB1 (80 ng/μl in sterile PBS), and an anti-IGF2 receptor antibody (20 ng/μl in sterile PBS) were prepared. The injections were carried out using a 26-gauge needle connected via polyethylene tubing to a Hamilton syringe at 0.125 μl per side and at a rate of 0.125 μl/min. The total amounts of the drugs injected in the brain were 250 ng (IGF2), 20 ng (JB1) and 5 ng (Anti-IGF2 receptor antibody). The injection needle was left in place for 2 min after the injection to allow complete dispersion of the solution. Postoperative analgesia was induced with a single injection of buprenorphine (0.1 mg/kg, i.p.) .
BrdU immunohistochemistry in the dentate gyrus
Mice were deeply anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and perfused transcardially with saline, followed by 4% paraformaldehyde in PBS. Their brains were removed, post-fixed in the same fixative, and then cryoprotected. Thick coronal brain sections of 20 μm were cut on a cryostat at −20°C. Every sixth section was collected between the stereotaxic coordinates −1.40 to −2.48 mm according to a brain atlas. The freefloating sections were first preincubated for 30 min in 0.3% hydrogen peroxide in PBS containing 0.3% Triton-X100 (PBST) to remove endogenous peroxidase activity, and then mounted on slides. Sections were heated in a microwave oven in a 0.01 M sodium citrate buffer (pH 6.0) for 10 min and then treated with 2 M HCl at 35°C for 30 min. After being rinsed for 10 min at room temperature in 0.1 M boric acid/NaOH (pH 8.5), they were blocked by 5% normal goat serum in PBST for 1 h at room temperature.
For BrdU staining, sections were incubated with a rat anti-BrdU monoclonal primary antibody (1:100, Abcam, UK) at 4°C overnight, followed by a biotin-conjugated goat anti-rat IgG (1:250, Abcam, UK) for 30 min at room temperature. Biotinylated secondary antibodies were detected using an ABC immunoperoxidase kit (Vector Laboratories, USA). Brown cytosolic products were obtained by a reaction with 3,3′-diaminobenzidine (Sigma, USA). The sections were counterstained with hematoxylin. For double staining of neuronal nuclei (NeuN) (a mature neuronal marker) and BrdU, sections were incubated with a mouse anti-NeuN monoclonal primary antibody (1:200, millipore, USA) and a rat anti-BrdU monoclonal primary antibody (1:100, Abcam, UK) at 4°C overnight, followed by an Alexa Fluor 594 anti-mouse IgG (1:200, Life Technologies, USA) and an 
Quantification of cell immunostaining
Every sixth section throughout the hippocampus (for a total of nine sections from each mouse) was processed for BrdU immunohistochemistry. All BrdU-labeled cells in the subgranular zone and granule cell layer were assessed using an Axio Imager upright microscope (Zeiss, Germany) and counted by an experimenter blinded to the condition. To distinguish single cells within clusters, all counts were performed at 400× magnification (objective; 40×). To obtain the total number of BrdUlabeled cells in the subgranular zone and granule cell layer, we multiplied the counted number of positive cells by six. Double stained cells were assessed using the Axio Imager upright microscope, scanned through the z axis, and analyzed at intervals of 1.0 μm, to exclude false double-positive cells due to the overlay of signals from different cells.
Data analysis
All data are expressed as the mean±S.E.M. The data were analyzed using one-way (Figs 
Results
Effects of galantamine and other cholinergic drugs on proliferation of newly divided cells in the dentate gyrus of the adult mouse hippocampus
The effects of a single injection of galantamine on proliferation of newly divided cells were examined in the dentate gyrus of the hippocampus (Fig. 1) . Figure 1a , b show representative photomicrographs of the localization and quantitative analysis of BrdU-positive cells, respectively. Most of the BrdU-labeled cells were found in the subgranular zone of the dentate gyrus in all groups, and galantamine (3 mg/kg, i.p.) significantly increased the number of BrdU-positive cells in the subgranular zone of the dentate gyrus (F 2,16 = 4.4, p < 0.05). It did not affect the number of BrdU-positive cells in the granule cell layer (F 2,16 = 0.3, p > 0.05). Figure 2 shows the effects of acute treatment with the acetylcholinesterase inhibitors physostigmine and donepezil and the nonselective muscarinic receptor agonist oxotremorine on newly divided cell proliferation. Physostigmine (0.1 mg/kg, i.p.) and oxotremorine (0.1 mg/kg, i.p.) significantly increased the number of BrdU-positive cells in the subgranular zone (F 2,23 = 9.9, p < 0.001). These drugs did not affect the number of BrdUpositive cells in the granule cell layer (F 2,23 = 0.3, p > 0.05). On the other hand, donepezil (1 and 3 mg/kg, i.p.) did not affect proliferation of newly divided cells (F 2,21 = 0.1, p > 0.05).
The effects of receptor antagonists against galantamine-induced increases in the number of BrdUpositive cells in the subgranular zone of the dentate gyrus were examined to clarify the receptor mechanisms for these effects of galantamine (Fig. 3) . Galantamineinduced increases in the number of BrdU-positive cells in the subgranular zone were blocked by the nonselective muscarinic receptor antagonist scopolamine (0.1 mg/kg, i.p.) and the preferential M 1 muscarinic receptor antagonist telenzepine (3 mg/kg, s.c.), but not by the nonselective nicotinic receptor antagonist mecamylamine (3 mg/kg, i.p.) or the selective α7 nicotinic receptor antagonist methyllycaconitine (6 mg/kg, i.p.). The dose of mechamylamine used here was enough to block nicotineinduced hypothermia and hypolocomotion in mice (Supplementary Figure S1) . Two-way ANOVA revealed a significant main effect of galantamine (F 1,62 = 16.9, p < 0.001) and these antagonists (F 4,62 = 4.4, p < 0.01), but there was no significant interaction between galantamine and treatment with these antagonists (F 4,62 = 2.1, p > 0.05). Scopolamine, telenzepine, mecamylamine, and methyllycaconitine did not affect the proliferation of newly divided cells when given alone.
Effects of acute galantamine treatment on the differentiation of newly divided cells in the dentate gyrus Newly divided cells in the dentate gyrus display typical features of mature neurons within 4 wk (Cameron and McKay, 2001) . It is not known whether galantamine affects the differentiation of newly divided cells. Using NeuN-positive and GFAP-positive cells, this study investigated the effects of acute galantamine treatment on the differentiation of newly divided cells in the dentate gyrus of the adult mouse hippocampus (Fig. 4) . Mice were sacrificed 28 d after the last BrdU injection and we counted the number of NeuN-and GFAP-positive cells among BrdU-labeled cells in the dentate gyrus. Galantamine (3 mg/kg, i.p.) significantly increased the number of NeuN/BrdU-positive cells in the subgranular zone and granule cell layer, and also significantly increased the number of GFAP/BrdU-positive cells in the subgranular zone. Galantamine did not alter the ratio of NeuN-or GFAP-positive cells to BrdU-labeled cells in the subgranular zone and granule cell layer, suggesting that the drug did not affect cell differentiation (Fig. 4) . The determination of the NeuN-positive and GFAP-positive cells was also confirmed by a confocal laser scanning microscope (Supplementary Figure S2) . Fig. 3 . Effects of scopolamine, telenzepine, mecamylamine, and methyllcaconitine on the galantamine-induced increase in newly divided cell proliferation in the dentate gyrus of the adult mouse hippocampus. Mice were injected intraperitoneally (i.p.) with galantamine (3 mg/kg) or saline. Scopolamine (0.1 mg/kg, i.p.), telenzepine (3 mg/kg, s.c.), mecamylamine (3 mg/kg, i.p.), methyllycaconitine (6 mg/kg, i.p.) or saline (i.p.) was administered 30 min before the galantamine or saline treatment. Twenty-four hours after the injection of galantamine or saline, 5-bromo-2′-deoxyuridine (BrdU) (50 mg/kg, i.p.) was injected twice at 12 h intervals. Animals were sacrificed 12 h after the last injection of BrdU, and BrdU-positive cells in the subgranular zone (SGZ) and granule cell layer (GCL) were counted. The data are expressed as the mean ± S.E.M of 6-9 mice/group. *p < 0.05, compared with the saline/saline-treated group; †p < 0.05, compared with the saline/galantamine-treated group; #p < 0.05, compared with the mecamylamine/saline-treated group; § §p < 0.01, compared with the methyllycaconitine/saline-treated group.
Effects of acute galantamine treatment on the survival of newly divided cells at different time points in the dentate gyrus
The effects of acute galantamine treatment on the survival of newly divided cells were examined at different time points in the dentate gyrus of the adult mouse hippocampus (Fig. 5) . Galantamine (3 mg/kg) was administered, when BrdU-labeled cells were 1, 2, and 4 wk old. Galantamine significantly promoted the survival of newly divided cells by 2 wk in the granule cell layer of the dentate gyrus. Galantamine-induced increases in cell survival were blocked by methyllycaconitine (6 mg/kg, i.p.) (Fig. 5b) but not by scopolamine (0.1 mg/kg, i.p.) (data not shown). Two-way ANOVA revealed a significant main effect of galantamine (F 1,28 = 7.7, p < 0.01), but not methyllycaconitine (F 1,28 = 3.6, p > 0.05), and there was a significant interaction between treatments (F 1,28 = 4.6, p < 0.05). On the other hand, galantamine did not affect the survival of newly divided cells at 1 and 4 wk (Fig. 5a, c) . Galantamine did not affect cell survival in the subgranular zone.
To study further the involvement of α7 nicotinic receptors in the survival of newly divided cells by 2 wk in the granule cell layer of the dentate gyrus, we examined the effects of acute treatment with PHA-543613, a selective α7 nicotinic receptor agonist (Wishka et al., 2006) (Fig. 6) . PHA-543613 (3 mg/kg, s.c.) significantly promoted the survival of 14-16-d-old newly divided cells in the granule cell layer of the dentate gyrus (F 2,20 = 13.0, p < 0.001). It did not affect cell survival in the subgranular zone. Furthermore, donepezil (3 mg/kg, i.p.) did not promote the survival of 14-16-d-old newly divided cells.
Effects of IGF2 on the survival of newly divided cells in the dentate gyrus of the adult mouse hippocampus
In previous studies, we showed that acute galantamine, but not donepezil, increased hippocampal IGF2 protein levels via α7 nicotinic receptor activation 24 h after the injection (Kita et al., 2013) . Figure 7a of recombinant IGF2 were similar to those of galantamine. Since IGF2 interacts with the IGF1 receptor and IGF2 receptor (Alberini and Chen, 2012; Fernandez and Torres-Alemán, 2012) , we examine which receptor is involved in the effects of galantamine on the survival of newly divided cells in the granule cell layer (Fig. 7c, d) . The specific inhibitor of the IGF1 receptor JB1 (20 ng) abolished galantamine-induced enhancement of cell survival in the granule cell layer. On the other hand, 5 ng of an anti-IGF2 receptor antibody, which completely abolished the memory enhancement of IGF2 injection (Chen et al., 2011) , did not affect galantamine-induced enhancement of cell survival in the granule cell layer. Both inhibitors did not affect cell survival in the subgranular zone.
Discussion
The present study shows that acute treatment with galantamine promotes the proliferation of neural progenitor cells and the production of mature granule neurons in the subgranular zone of the hippocampal dentate gyrus. This effect is in agreement with the previous observation that daily galantamine for 14 d increases BrdU-labeled cells in the subgranular zone of the dentate gyrus in mice (Jin et al., 2006) . The effects of galantamine on cell proliferation were blocked by the nonselective muscarinic receptor antagonist scopolamine and the preferential M 1 muscarinic receptor antagonist telenzepine, but not by the nonselective nicotinic receptor antagonist mecamylamine and the selective α7 nicotinic receptor antagonist methyllycaconitine. Furthermore, we found that the nonselective muscarinic receptor agonist oxotremorine and the cholinesterase inhibitor physostigmine, like galantamine, promoted the proliferation of the newly divided cells. These findings suggest that the effects of galantamine on the proliferation of neural progenitor cells are mediated by activation of the M 1 muscarinic receptor. Indeed, the M 1 muscarinic receptor is expressed in newly divided cells in the subgranular zone of the dentate gyrus (Mohapel et al., 2005; Kaneko et al., 2006) . Furthermore, an in vitro study showed that muscarine increased proliferation of P19 progenitor cells and this effect was blocked by pirenzepine (Resende et al., 2008) .
Many newborn neurons in the dentate gyrus of the adult hippocampus die during maturation within 4 wk after birth (Cameron and McKay, 2001) , and only a small proportion of newborn neurons are functionally integrated into the existing hippocampal circuitry (Zhao et al., 2008) . Especially during 1-3 wk after birth, newborn neurons are immature and display unique physiological properties (e.g. morphological and synaptic changes) (Espósito et al., 2005; Ge et al., 2006; Zhao et al., 2006) , and thus, the survival of these neurons probably contributes to hippocampal-dependent memory formation (Tashiro et al., 2007; Veyrac et al., 2013 ). The present study shows that acute treatment with galantamine specifically promotes the survival of newly divided cells at 14-16 d in the granule cell layer of the hippocampal dentate gyrus and this effect is blocked by the selective α7 nicotinic receptor antagonist methyllycaconitine. We also found that the selective α7 nicotinic receptor agonist PHA-543613, but not donepezil, promoted the survival of newly divided cells in the granule cell layer.
These observations suggest that galantamine promotes the survival of newly divided cells at 14-16 d via activation of the α7 nicotinic receptor. It should be noted that the effects of galantamine on the survival of newly divided cells at 14-16 d was observed at 1 and 3 mg/kg, whereas that of galantamine on the proliferation of newly divided cells was observed only at 3 mg/kg. That is, there is a difference in sensitivity to galantamine between muscarinic-receptor-mediated cell proliferation and nicotinic-receptor-mediated cell survival. In line with this, we have recently found that galantamine at doses of 0.3-3 mg/kg increased hippocampal IGF2 levels and this effect was mediated by activation of the α7 nicotinic receptor (Kita et al., 2013) . These findings suggest that galantamine-induced increases in hippocampal IGF2 are involved in the effects of galantamine on cell survival. Concerning the role of IGF2 in hippocampal neurogenesis, Bracko et al. (2012) showed that IGF2 regulates proliferation of hippocampal neural stem cells through AKT-dependent signaling. AKT appears to be involved in cell survival and anti-apoptotic signaling (Song et al., 2005) . Furthermore, Agis-Balboa et al. (2011) reported that hippocampal IGF2 is involved in contextual fear extinction, and that IGF signaling specifically promotes the survival of 17-19-d-old newborn hippocampal neurons. Taken together, it is likely that nicotinicreceptor-mediated cell survival by galantamine is mediated by IGF2 expression.
To clarify the involvement of IGF2 in galantamineinduced survival of hippocampal immature cells, we examined the effects of direct injection of IGF2 and inhibitors of IGF2 signal on the survival of newly divided cells at 14-16 d. The present study shows that bilateral injection of recombinant IGF2 promotes cell survival, which is similar to the effects of galantamine. We did not study whether IGF2 injection affects proliferation of newly divided cells, but Bracko et al. (2012) reported that addition of IGF2 to neural stem cells of normal mice in vitro had only a minor effects on their proliferation, and Ouchi et al. (2013) recently showed that injection of IGF2 to normal mice in vivo did not affect neural progenitor cell proliferation. We further found that the effects of galantamine on the survival of immature cells were blocked by the IGF1 receptor antagonist JB1, but not an anti-IGF2 receptor antibody. This experiment using a neutralizing antibody and a pharmacological inhibitor suggests that galantamine promotes the survival of immature cells at 14-16 d via an IGF1 receptormediated IGF2 signal. It is not known why the effects of IGF2 are specific for the survival of immature cells.
Galantamine is typically used in a chronic fashion to treat Alzheimer's patients. Jin et al. (2006) reported that chronic treatment with galantamine increased BrdU labeling of cells in the hippocampal dentate gyrus and forebrain subventricular zone of the adult mouse brain. The finding suggests that the effect of galantamine on neurogenesis may contribute to the therapeutic effect. In the present study, galantamine was acutely administered to investigate the effect on each process of the neurogenesis, such as proliferation of the newborn cells and survival of the cells. We found that galantamine promotes the proliferation of the newly divided cells and survival of the cells via the activation of the M 1 muscarinic and α7 nicotinic receptors, respectively. The present study also showed that donepezil did not affect the proliferation of newly divided cells. This contrasts to the previous observations using a multiple doses of donepezil (Kaneko et al., 2006; Kotani et al., 2006 the antagonistic effect of donepezil on the muscarinic receptor may result in the lack of the effect of acute donepezil, but the effect may be desensitized by its chronic administration.
In conclusion, we demonstrate that galantamine promotes the proliferation of neural progenitor cells in the subgranular zone via activation of the M 1 muscarinic receptor and it promotes the survival of the newly divided cells in the granule cell layer via activation of the α7 nicotinic receptor. Furthermore, we found that direct injection of IGF2 promotes the survival of immature cells in the granule cell layer and the effects of galantamine on cell survival were blocked by an inhibitor of IGF2 receptor signaling (the IGF1 receptor antagonist JB1). These findings, taken together with the recent finding that galantamine increases hippocampal IGF2 levels (Kita et al., 2013) , suggest that IGF2 signaling plays a key role in galantamine-induced survival of immature cells in the granule cell layer (Fig. 8) . Adult hippocampal neurogenesis is impaired in Alzheimer's disease (Crews and Masliah, 2010; Lazarov and Marr, 2010; Curtis et al., 2012) and may be a target for the treatment of mental illness including Alzheimer's disease patients (DeCarolis and Eisch, 2010; Shruster and Offen, 2014) . Although it is not known whether galantamine increases hippocampal IGF2 levels and promotes hippocampal neurogenesis in the pathological conditions, we speculate that the increases in hippocampal IGF2 levels and neurogenesis may be involved in the clinical effect of galantamine.
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